- $389.11m
- $225.45m
- 44
- 24
- 93
- 53
Annual income statement for PepGen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 1.88 | 27.1 | 68.3 | 84.8 | 97.7 |
| Operating Profit | -1.88 | -27.1 | -68.3 | -84.8 | -97.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.89 | -27.3 | -65.4 | -78.6 | -90.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.89 | -27.3 | -69.1 | -78.6 | -90 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.89 | -27.3 | -69.1 | -78.6 | -90 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.89 | -27.3 | -69.1 | -78.6 | -90 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.084 | -1.22 | -2.91 | -3.3 | -2.85 |